Terug naar bedrijfspagina

Nieuws over MDxHealth

07/11/2024 MDxHealth - Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 (07.11.2024)

26/09/2024 MDxHealth - Announces Launch of Offering of Ordinary Shares (26.09.2024)

22/08/2024 MDxHealth - Reports Q2 and Half Year 2024 Results (22.08.2024)

08/07/2024 MDxHealth - Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance (08.07.2024)

16/05/2024 Mdxhealth - to Present at Upcoming Investor Conferences (16.05.2024)

01/05/2024 MDxHealth - Reports Q1-2024 Results and Announces Growth Capital from OrbiMed (01.05.2024)

13/03/2024 Mdxhealth - Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering (13.03.2024)

07/03/2024 Mdxhealth - Announces Fourth Quarter and Full-Year 2023 Financial Results (07.03.2024)

09/01/2024 MDxHealth - Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance (09.01.2024)

18/12/2023 MDxHealth - Announces Completion of Transition to Single Listing on Nasdaq (18.12.2023)

27/11/2023 MDxHealth - Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq (27.11.2023)

09/11/2023 MDxHealth - Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 (09.11.2023)

06/11/2023 MDxHealth - Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation (06.11.2023)

10/10/2023 MDxHealth - Reports Preliminary Q3-2023 Revenues (10.10.2023)

03/10/2023 MDxHealth - Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting (03.10.2023)

27/09/2023 Mdxhealth - Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer (27.09.2023)

23/08/2023 MDxHealth - Reports Q2 and Half Year 2023 Results (23.08.2023)

10/08/2023 MDXHEALTH - Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test (10.08.2023)

16/05/2023 MDxHealth - Reports Q1-2023 Results (16.05.2023)

20/04/2023 MDXHEALTH - Foundational LCD Covers Select mdx for Prostate Cancer (20.04.2023)

13/03/2023 MDxHealth - Confirms No Exposure to Silicon Valley Bank or Silvergate Bank (13.03.2023)

09/03/2023 MDxHealth - Reports Financial Year 2022 Results and Provides Business Update and Outlook for 2023 - Update of Outstanding Shares and Voting Rights (09.03.2023)

07/03/2023 MDxHealth - Announces Exercise of Option (07.03.2023)

14/02/2023 MDxHealth - Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test (14.02.2023)

03/02/2023 MDxHealth - Announces Pricing of Offering of ADSs in the United States (03.02.2023)

02/02/2023 MDxHealth - Announces Launch of Offering of ADSs in the United States (02.02.2023)

20/01/2023 MDxHealth - Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test (20.01.2023)

10/01/2023 MDxHealth - Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance (10.01.2023)

30/11/2022 MDxHealth - Provides Business Update (30.11.2022)

28/10/2022 MDxHealth - rapporteert resultaten Q3-2022 (28.10.2022)

26/08/2022 MDxHealth - Reports Half Year 2022 Results (25.08.2022)

03/08/2022 Mdxhealth - Acquires Oncotype DX GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results (03.08.2022)

20/05/2022 MDxHealth - Palmetto GBA émet la couverture LCD de base pour SelectMDx® for Prostate Cancer (20.05.2022)

28/04/2022 MDxHealth - Reports Q1-2022 Results (28.04.2022)

03/03/2022 MDxHealth - Reports Financial Year 2021 Results and Provides Outlook and Guidance for 2022 (03.03.2022)

09/11/2021 MDxHealth - Announces Completion of Initial Public Offering of ADSs in the United States (09.11.2021)

04/11/2021 MDxHealth - Announces Pricing of Initial Public Offering of ADSs in the United States (04.11.2021)

28/10/2021 MDxHealth - Announces Launch of Proposed Initial Public Offering of ADSs in the United States (28.10.2021)

21/10/2021 MDxHealth - Provides Q3-2021 Business Update (21.10.2021)

14/10/2021 MDxHealth - dient een registratieverklaring in voor de voorgestelde eerste openbare aanbieding in de Verenigde Staten (14.10.2021)

26/08/2021 MDxHealth - Reports Half Year 2021 Results (26.08.2021)

21/05/2021 MDxHealth - Announces Favorable Draft Medicare Coverage for the SelectMDx for Prostate Cancer Test (21.05.2021)

21/04/2021 MDxHealth - Provides Q1-2021 Business Update (21.04.2021)

03/03/2021 MDxHealth Reports Financial Year 2020 Results and Provides Outlook for 2021 (03.03.2021)

21/10/2020 MDxHealth - Provides Q3-2020 Business Update (21.10.2020)

26/08/2020 MDxHealth - Reports Half Year 2020 Results (26.8.2020)

07/08/2020 MDxHealth - Update on Medicare Coverage for SelectMDx (7.8.2020)

27/07/2020 MDxHealth - Announces Inclusion of SelectMDx in 2020 NCCN Guidelines for Prostate Cancer Early Detection (27.7.2020)

28/04/2020 MDxHealth - Announces its Annual and Extraordinary shareholders meeting (28.4.2020)

27/04/2020 MDxHealth - Announces Growth Investment from MVM Partners (27.4.2020)

20/04/2020 MDxHealth - to Receive $2.3 million “Paycheck Protection Program” Loan under the U.S. CARES Act (20.4.2020)

09/04/2020 MDxHealth Provides Q1-2020 Business Update (9.4.2020)

01/04/2020 MDxHealth Updates 2020 Reporting Calendar and Provides Initial View on Coronavirus Situation (1.4.2020)

26/02/2020 MDxHealth Reports - Financial Year 2019 Results and Provides Outlook for 2020 (26.2.2020)

12/11/2019 MDxHealth Provides Q3-2019 Business Update (12.11.2019)

29/08/2019 MDxHealth Reports Half Year 2019 Financial Results and Strategic Update (29.8.2019)

26/08/2019 MDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx Test (26.8.2019)

21/06/2019 Mdxhealth - Extraordinary General Shareholders’ Meeting (21.6.2019)

11/06/2019 MDxHealth- Multi-center Study Validates SelectMDx's High Negative Predictive Value and Sensitivity (10.6.2019)

24/04/2019 MDxHealth - provides Q1 2019 business update (24.4.2019)

15/02/2019 MDXHealth - MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis (15.2.2019)

14/02/2019 MDxHealth Signs Partnership with LifeLabs to Make SelectMDx available in Canada (14.2.2019)

24/01/2019 MDxHealth (R) SelectMDx Outperforms Prostate Health Index (phi) Blood Test for Detecting High-Grade Prostate Cancer (24.1.2019)

14/01/2019 MDxHealth Provides Business Update (14.1.2019)

26/11/2018 MDX HEALTH-Amerikaans klinisch beoordelingsorgaan staat New York verleent MDxHealth goedkeuring voor SelectMDx urinetest voor prostaatkanker (26.11.2018)

07/11/2018 MDxHealth-SelectMDx improves prostate biopsy decision-making in urology practices (7.11.2018)

24/10/2018 MDxHealth: alweer teleurstelling (KBC)

23/10/2018 MDxHealth publiceert business update over de eerste negen van maanden van 2018 (23.10.2018)

30/08/2018 MDxHealth (R): MDxHealth Reports Half Year 2018 Results (30.8.2018)

28/08/2018 MDxHealth -SelectMDx Cost-effective in Four European Countries (28.8.2018)

10/08/2018 MDxHealth Shareholder Transparency Declaration (10.8.2018)

10/08/2018 MDxHealth kennisgeving publicatie halfjaarcijfers 2018 op 30 augustus (10.8.2018)

07/08/2018 MDxHealth- Transparantieverklaring (7.8.2018)

07/08/2018 MDxHealth - MDxHealth Shareholder Transparency Declaration (7.8.2018)

26/04/2018 Mooie kwartaalgroei bij MDx Health (KBC)

08/05/2017 MDxHealth kan niet (meer) bekoren (KBC Group - The Front Row)

17/05/2016 2016 05 - Interview met ceo Jan Groen

08/10/2015 Bolero: aandeel in de kijker MDxHealth

16/09/2015 Bolero: MDxHealth met overnamenieuws naar Capital Markets Day

02/09/2015 Bolero: Biotechfocus MDxHealth

20/05/2015 Bolero: aandeel in de kijker is MDxHealth

06/05/2015 Bolero: aandeel in de kijker is MDxHealth